The aim of this work was to design a therapeutic bsAb that would be directed to the tumor, through its anti-tumor-associated antigen moiety (TAA, anti-BCMA), and then induce immune cell activation and killing in the microenvironment, by blocking in situ the PD1-PDL1 axis. The gene discussed is TNFRSF17; the disease is neoplasm.